What is Mologic?
Mologic has established itself as a leader in the development of rapid diagnostic products and technology. Since re-establishing its independence in 2014, the company has successfully advanced a portfolio of 10 products to pre-market evaluation, with three receiving CE mark approval in 2016. Mologic's innovation extends beyond human healthcare, encompassing active programs in large animal disease diagnostics and vaccine innovation. The company also provides high-value contract partnering projects, leveraging its ISO13485 certified low-volume manufacturing facility to undertake diverse project challenges from conception to initial product volumes. This comprehensive service offering, from reagents to innovation and manufacturing, positions Mologic as a versatile partner in the life sciences industry.
How much funding has Mologic raised?
Mologic has raised a total of $14.9M across 4 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Grant
$4.8M
Series B
$915K
Private Equity (2015): $4.6M with participation from Calculus Capital
Series A (2015): $4.6M led by Calculus Capital
Grant (2016): $4.8M supported by Bill & Melinda Gates Foundation
Series B (2018): $915K featuring Innovate UK
Key Investors in Mologic
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare businesses.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is an organization dedicated to supporting individuals experiencing hunger and extreme poverty by enabling them to lead healthier lives.
Innovate UK
Innovate UK is an innovation agency that supports business growth and technological advancement, with roots as the Technology Strategy Board.
What's next for Mologic?
The recent major strategic investment in Mologic signals a pivotal moment for the company, likely enabling accelerated product development, market penetration, and potentially scaling of manufacturing capabilities. Given the company's established product pipeline and its expansion into animal health diagnostics, this capital infusion is expected to fuel further innovation and commercialization efforts. Mologic's strategic focus on both human and animal health, coupled with its contract partnering services, suggests a multi-faceted growth strategy. Future developments may include broader regulatory approvals, expanded global distribution, and continued advancements in diagnostic technologies, solidifying its position in the competitive healthcare market.
See full Mologic company page
